01:22:19 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Prenumeration

Kalender

2025-01-29 Bokslutskommuniké 2024
2024-10-29 Kvartalsrapport 2024-Q3
2024-07-30 Kvartalsrapport 2024-Q2
2024-05-17 Ordinarie utdelning ZICC 0.00 SEK
2024-04-29 Kvartalsrapport 2024-Q1
2024-01-26 Bokslutskommuniké 2023
2023-10-25 Kvartalsrapport 2023-Q3
2023-07-18 Kvartalsrapport 2023-Q2
2023-06-21 Ordinarie utdelning ZICC 0.00 SEK
2023-06-20 Årsstämma 2023
2023-04-26 Kvartalsrapport 2023-Q1
2023-01-27 Bokslutskommuniké 2022
2022-10-27 Kvartalsrapport 2022-Q3
2022-08-23 Kvartalsrapport 2022-Q2
2022-04-29 Ordinarie utdelning ZICC 0.00 SEK
2022-04-28 Årsstämma 2022
2022-04-28 Kvartalsrapport 2022-Q1
2022-02-17 Bokslutskommuniké 2021
2022-01-18 Extra Bolagsstämma 2022
2021-10-28 Kvartalsrapport 2021-Q3
2021-08-26 Kvartalsrapport 2021-Q2
2021-04-28 Ordinarie utdelning ZICC 0.00 SEK
2021-04-27 Årsstämma 2021
2021-04-23 Kvartalsrapport 2021-Q1
2021-02-11 Bokslutskommuniké 2020
2020-11-06 Kvartalsrapport 2020-Q3
2020-08-20 Kvartalsrapport 2020-Q2
2020-06-17 Ordinarie utdelning ZICC 0.00 SEK
2020-06-16 Årsstämma 2020
2020-04-17 Kvartalsrapport 2020-Q1
2020-02-13 Bokslutskommuniké 2019
2019-11-07 Kvartalsrapport 2019-Q3
2019-08-21 Kvartalsrapport 2019-Q2
2019-05-20 Årsstämma 2019
2019-05-10 Ordinarie utdelning ZICC 0.00 SEK
2019-05-09 Kvartalsrapport 2019-Q1

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriLäkemedel & Handel
Ziccum är ett svenskt läkemedelsbolag som utvecklar nya beredningar av biologiska läkemedel. Med bolagets patenterade teknologi LaminarPace utvecklas torra beredningsformer av produkter som i nuläget finns i vätskeform. Störst versamhet återfinns runtom Norden, samt utöver huvudverksamheten erbjuder bolaget diverse relaterade produkter. Bolagets huvudkontor ligger i Lund.
2024-01-10 09:20:00

Ziccum and its Biotech Corporation collaboration partner have now reviewed the outcomes of the LaminarPace Feasibility study of mRNA/LNP materials, under the agreement signed on May 9th 2023. The study was very successful, and both parties confirm consistent, positive readouts in the Study’s major parameters.

 
The joint assessment meeting reviewing the readouts took place on January 9, 2024. It concluded that the LaminarPace treatment performed very successfully in the Study’s agreed-upon metrics:

mRNA activity: the assessment concluded that the resulting dry powder material demonstrated excellent mRNA activity, when reconstituted and tested in in-vitro cell studies. This is a must for the resulting mRNA treatment to have its effect, for vaccine immunisation or therapeutic effect.

Encapsulation efficiency: the assessment concluded that the LaminarPace treatment resulted in well-preserved mRNA content in LNP particles with adequate encapsulation efficiency. This is an important metric in the production economics of mRNA/LNP, preserving the very expensive mRNA materials.

Particle preservation and distribution: the assessment concluded that the treatment resulted in well preserved lipid nanoparticles with good particle size and preserved size distribution. This is important for having a final drug composition which can be administered to patients.

Product reconstitution: the partner assessment confirmed the consistent Ziccum findings that LaminarPace-treated material can be reconstituted (dissolved back into liquid) very quickly and smoothly, with no foaming, precipitation, or other practical issues.

The Ziccum evaluation and the Biotech Corporation partner’s evaluation both delivered consistent results that matched very closely.
 
Based on these clear, satisfactory results, a continued dialogue on the potential next phase of collaboration in potential applications may be initiated.

Ziccum CEO Ann Gidner: “These results, from a world-leading player in the field, confirm LaminarPace’s ability to turn mRNA/LNP liquid biological material into a thermostable dry powder, with all its advantages, retaining excellent mRNA activity in cells. This is exciting and rewarding news. We are grateful for excellent partner interaction, and our partner concluding that the collaboration was a success. Let me express my appreciation to the Ziccum team for their great efforts delivering these results”.

Ziccum Chairman Fredrik Sjövall: “It is of utmost importance to Ziccum to have this validation of the applicability of LaminarPace technology also for mRNA/LNP treatments. We are keenly looking forward to the potential of applying LaminarPace in this field, with many potential applications and partners.”